Table II.
Different types of drugs designed based on ADCs that are at different stages of clinical confirmation
| Agent | Linker | Warhead | Target | Phase |
|---|---|---|---|---|
| IMMU-110 | Hydrazone | Doxorubicin | CD74 | 2 |
| Mylotarg | Hydrazone | Calicheamicin | CD33 | Withdrawn |
| CMC-544 | Hydrazone | Calicheamicin | CD22 | 3 |
| SAR3419 | Disulfide | DM4 | CD19 | 2 |
| BT-062 | Disulfide | DM4 | CD138 | 1 |
| BAY-94-9343 | Disulfide | DM4 | Mesothelin | 1 |
| SAR-566658 | Disulfide | DM4 | DS6 | 1 |
| IMGN901 | Disulfide | DM1 | CD56 | 2 |
| Kadcyla | Thioether | DM1 | HER2 | Licensed |
| IMGN529 | Thioether | DM1 | CD37 | 1 |
| SGN-75 | MC | MMAF | CD70 | 1 |
| Adcetris | Peptide (Val-Cit) | MMAE | CD30 | Licensed |
| RG-7596 | Peptide (Val-Cit) | MMAE | CD79b | 2 |
| CDX-011 | Peptide (Val-Cit) | MMAE | GPNMB | 2 |
| PSMA-ADC | Peptide (Val-Cit) | MMAE | PSMA | 2 |
| ASG-5ME | Peptide (Val-Cit) | MMAE | AGS-5 | 1 |
| IMUU-130 | Peptide (Phe-Lys) | SN-38 | CEACAM5 | 2 |